Project Grant HT94252410546
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19111, USA
Similar Awards
The Department of Defense (DoD) has awarded a $846,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Institute For Cancer Research, a non-profit research organization, to investigate PALB2 mutant breast cancer. The funding supports a 3-year research project from August 1, 2024 to July 31, 2027. As the prime grantee, The Institute For Cancer Research will conduct innovative scientific studies and clinical trials focused on developing new treatments...
This $838,911 Project Grant awarded by the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports research by The Institute For Cancer Research to identify regulators of PALB2 function and PARP inhibitor resistance in triple-negative breast cancer. The 3-year award, beginning January 2024, will fund work to advance the understanding of genetic and molecular mechanisms underlying treatment resistance in this aggressive form of breast cancer. As a prime...
The U.S. Defense Health Agency awarded a $1,880,000 Project Grant to The Institute for Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding will support a 3-year research project to study the SRPK1-AKT signaling axis in endometrial cancer. As a prime grantee, The Institute for Cancer Research will conduct preclinical testing and analysis to develop new approaches for cancer prevention and...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $985,876 project grant to The Trustees of Columbia University in the City of New York to conduct research on "TARGETING PARP1 TRAPPING TO OVERCOME PARP INHIBITOR RESISTANCE FOR BRCAMUT OVARIAN CANCERS." The grant, which runs from April 15, 2024 to April 18, 2024, aims to develop new treatments for ovarian cancer in patients with BRCA mutations by investigating strategies to...
The U.S. Department of Defense's Defense Health Agency awarded a $752,000 Project Grant to The Institute For Cancer Research, a subsidiary of Temple University, to investigate therapeutic response disparities in locally advanced rectal cancer. This grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative and impactful research....
The U.S. Defense Health Agency awarded a $700,788 Project Grant to The Institute For Cancer Research, a non-profit subsidiary of Temple University, under the Military Medical Research and Development program (CFDA 12.420). The funding supports a 3-year research project to study the targeting of the nuclear necroptosis pathway in the pancreatic cancer microenvironment. As a prime grantee, The Institute For Cancer Research will conduct preclinical testing, biomarker analysis, and other specialized...
This $188,000 Project Grant was awarded on April 1, 2024 by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), to The Institute For Cancer Research. The grant funds a research project titled "P2X7 RECEPTOR AS A NOVEL THERAPEUTIC TARGET IN PROSTATE CANCER" that will be conducted from April 1, 2024 through March 31, 2026. The Institute For Cancer Research, a non-profit subsidiary of Temple University, will carry out biomedical research...
This federal Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development program (CFDA 12.420), provides $1,178,136.00 to The Trustees of the University of Pennsylvania to conduct research on exploiting the absence of TP53 mutations in epithelial ovarian cancer using next-generation p53-stabilizing agents. The research aims to transform healthcare for military service members and the broader public by investigating innovative...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,191,000 Project Grant to the Baruch S. Blumberg Institute in Doylestown, PA. The grant, which runs from August 1, 2024 to July 31, 2027, supports the institute's research into "Novel Mechanisms Governing Human Breast Cancer Chromosomal Instability." The Baruch S. Blumberg Institute, a non-profit biomedical research organization, will use this funding to conduct innovative scientific...
The University of Pittsburgh was awarded a $954,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research from May 2023 to May 2026 aimed at epigenetic reprogramming to target senescent ovarian cancer cells and overcome therapeutic resistance. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research to transform military and public...